SG11201810358YA - Compositions and methods for treating negative symptoms in non-schizophrenic patients - Google Patents
Compositions and methods for treating negative symptoms in non-schizophrenic patientsInfo
- Publication number
- SG11201810358YA SG11201810358YA SG11201810358YA SG11201810358YA SG11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- methods
- pct
- negative symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341590P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034030 WO2017205393A1 (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810358YA true SG11201810358YA (en) | 2018-12-28 |
Family
ID=58794265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190216793A1 (enExample) |
| EP (1) | EP3463356A1 (enExample) |
| JP (3) | JP2019516756A (enExample) |
| KR (2) | KR20240005110A (enExample) |
| CN (3) | CN113694065A (enExample) |
| PH (1) | PH12018502445A1 (enExample) |
| SG (2) | SG11201810358YA (enExample) |
| TW (2) | TWI820001B (enExample) |
| WO (1) | WO2017205393A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| CA3067031A1 (en) | 2017-06-21 | 2018-12-27 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| MA53437A (fr) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences Inc | Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection |
| TWI879755B (zh) * | 2020-02-20 | 2025-04-11 | 日商田邊三菱製藥股份有限公司 | 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途 |
| KR102360137B1 (ko) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | 카트리지 및 이를 포함하는 에어로졸 생성 장치 |
| PE20231815A1 (es) * | 2021-02-09 | 2023-11-16 | Xenon Pharmaceuticals Inc | Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia |
| US20240212824A1 (en) * | 2022-12-21 | 2024-06-27 | Woebot Labs, Inc. | Administering a digital therapeutic using a device interface to treat anxiety or depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151533A0 (en) | 2000-02-29 | 2003-04-10 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| CN101378752A (zh) * | 2006-02-07 | 2009-03-04 | 田边三菱制药株式会社 | 4-酰氨基吡啶衍生物介导的神经发生 |
| KR20080089279A (ko) * | 2007-03-30 | 2008-10-06 | 미쓰비시 타나베 파마 코퍼레이션 | 우울증의 예방 및/또는 치료제 |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| DK2595484T3 (en) * | 2010-07-20 | 2018-01-22 | Minerva Neurosciences Inc | USE OF CYCLIC AMIDE DERIVATIVES FOR TREATMENT OF SLEEP DISORDERS |
| WO2012012543A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals Inc. | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP3144308B1 (en) * | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| JP2018501217A (ja) * | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
-
2017
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/zh active Pending
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/zh active Pending
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en not_active Withdrawn
- 2017-05-23 TW TW106117023A patent/TWI820001B/zh active
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en not_active Ceased
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/ko not_active Ceased
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/zh active Pending
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/ja active Pending
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/ko not_active Ceased
- 2017-05-23 TW TW112118953A patent/TWI851224B/zh active
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en not_active Abandoned
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/ja active Pending
-
2024
- 2024-10-02 JP JP2024173054A patent/JP2025000921A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN109689055A (zh) | 2019-04-26 |
| US20190216793A1 (en) | 2019-07-18 |
| PH12018502445A1 (en) | 2019-09-09 |
| CN113694065A (zh) | 2021-11-26 |
| US20230190726A1 (en) | 2023-06-22 |
| KR20240005110A (ko) | 2024-01-11 |
| TWI820001B (zh) | 2023-11-01 |
| WO2017205393A1 (en) | 2017-11-30 |
| SG10202011470UA (en) | 2021-01-28 |
| KR20190013846A (ko) | 2019-02-11 |
| TW201808288A (zh) | 2018-03-16 |
| CN113908156A (zh) | 2022-01-11 |
| TW202335672A (zh) | 2023-09-16 |
| JP2019516756A (ja) | 2019-06-20 |
| JP2025000921A (ja) | 2025-01-07 |
| TWI851224B (zh) | 2024-08-01 |
| EP3463356A1 (en) | 2019-04-10 |
| JP2022188185A (ja) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201804100UA (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |